Community Bank N.A. Has $4.12 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

Community Bank N.A. grew its stake in Amgen Inc. (NASDAQ:AMGN) by 2.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,804 shares of the medical research company’s stock after acquiring an additional 305 shares during the period. Community Bank N.A.’s holdings in Amgen were worth $4,119,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Napatree Capital LLC raised its stake in shares of Amgen by 66.4% in the fourth quarter. Napatree Capital LLC now owns 2,655 shares of the medical research company’s stock worth $692,000 after acquiring an additional 1,059 shares during the last quarter. Meridian Wealth Advisors LLC raised its stake in shares of Amgen by 0.7% during the fourth quarter. Meridian Wealth Advisors LLC now owns 8,164 shares of the medical research company’s stock worth $2,128,000 after buying an additional 54 shares during the last quarter. Stevens Capital Management LP bought a new stake in shares of Amgen during the fourth quarter worth approximately $1,785,000. Richwood Investment Advisors LLC raised its stake in shares of Amgen by 5.0% during the fourth quarter. Richwood Investment Advisors LLC now owns 4,338 shares of the medical research company’s stock worth $1,131,000 after buying an additional 206 shares during the last quarter. Finally, Mosley Wealth Management raised its stake in shares of Amgen by 15.0% during the fourth quarter. Mosley Wealth Management now owns 1,474 shares of the medical research company’s stock worth $415,000 after buying an additional 192 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen Price Performance

NASDAQ:AMGN opened at $316.04 on Friday. The firm has a market cap of $169.78 billion, a price-to-earnings ratio of 41.86, a P/E/G ratio of 2.63 and a beta of 0.53. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The firm’s 50-day simple moving average is $297.24 and its 200 day simple moving average is $298.80.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be paid a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.01%. Amgen’s payout ratio is currently 126.09%.

Insider Buying and Selling

In related news, EVP David M. Reese sold 25,225 shares of Amgen stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the sale, the executive vice president now directly owns 36,922 shares in the company, valued at $11,240,533.68. This trade represents a 40.59 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of Amgen stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the sale, the executive vice president now owns 28,987 shares in the company, valued at approximately $8,496,669.44. This represents a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock worth $20,644,335 in the last ninety days. Company insiders own 0.69% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Citigroup reissued a “neutral” rating on shares of Amgen in a research note on Wednesday, February 5th. Royal Bank of Canada reissued an “outperform” rating and set a $324.00 price target on shares of Amgen in a research note on Friday, January 24th. Piper Sandler Companies reissued an “overweight” rating and set a $310.00 price target on shares of Amgen in a research note on Thursday, January 2nd. Piper Sandler upped their target price on shares of Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Finally, Redburn Partners lowered their target price on shares of Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Amgen has an average rating of “Hold” and a consensus price target of $314.04.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.